MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00586-025-09600-7

Медицинская библиотека · European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2025

Efficacy of low-dose Escherichia coli-derived recombinant human bone morphogenetic protein-2 in minimally invasive transforaminal lumbar interbody fusion.

Kang Tae Hoon, Han Jeongwoon, Cho Minjoon, Lee Jae Hyup

СтатьяПеревод в очереди

Аннотация

PURPOSE: Minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) offers advantages over open procedures but is limited by the reduced availability of autologous bone. Escherichia coli-derived recombinant human bone morphogenetic protein-2 (E.BMP-2) has emerged as a scalable osteoinductive alternative, though its application in MIS-TLIF remains unstudied. This study aimed to evaluate the efficacy and safety of E.BMP-2 combined with hydroxyapatite (HA) carriers in the context of MIS-TLIF.

METHODS

Seventy patients (85 fusion levels) who underwent one- or two-level MIS-TLIF for degenerative lumbar conditions between 2016 and 2024 were included, with a minimum follow-up of one year. The E.BMP-2 group (34 patients, 39 levels) received local bone graft and allogenic cancellous bone graft along with a fixed dose of 1 mg E.BMP-2. The control group (36 patients, 46 levels) received local bone graft and allogenic cancellous bone graft only. Fusion was assessed using dynamic radiographs and CT imaging. Solid fusion on radiographs was defined as segmental motion < 3°, and on CT as continuous trabecular bone bridging between the upper and lower endplates. Clinical outcomes were evaluated using the visual analog scale (VAS) for back and leg pain, the Oswestry Disability Index (ODI), and the Functional Rating Index (FRI). Perioperative and delayed complications-including fever, elevated inflammatory markers, seroma formation, heterotopic ossification, and cage subsidence-were assessed via imaging and medical records.

RESULTS

The E.BMP-2 group demonstrated significantly higher fusion rates (radiographs: 97.4% vs. 78.3%, p = 0.001; CT: 89.7% vs. 63.0%, p = 0.005) without an increase in complications. No cases of seroma, heterotopic ossification, or reoperation were observed in the E.BMP-2 group. A standardized application protocol using 1 mg of E.BMP-2 per patient, combined with a containment technique, likely contributed to these favorable outcomes. Although clinical improvements were similar between groups, the rate of cage subsidence was significantly lower in the E.BMP-2 group at 6 and 12 months.

CONCLUSION

Low-dose E.BMP-2 appears to be a safe and effective osteoinductive adjunct for MIS-TLIF, particularly in cases with limited autologous bone. Appropriate carrier selection, dosing, and containment techniques are key to optimizing outcomes.

Для цитирования: Kang Tae Hoon, Han Jeongwoon, Cho Minjoon, Lee Jae Hyup. Efficacy of low-dose Escherichia coli-derived recombinant human bone morphogenetic protein-2 in minimally invasive transforaminal lumbar interbody fusion.. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 2025. DOI: 10.1007/s00586-025-09600-7.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.